Helicobacter pylori Triggers Development of Stomach Disease
|
By LabMedica International staff writers Posted on 23 Jan 2020 |

Image: Immunostaining of Helicobacter pylori infection in a gastric foveolar pit demonstrated in endoscopic gastric biopsy (Photo courtesy of KGH).
Helicobacter pylori is a paradigm persistent pathogen colonizing about 50% of the human world population and represents a major risk factor for chronic gastritis, peptic ulceration and gastric malignancies.
Toll-like receptor TLR5 recognizes a conserved domain, termed D, that is present in flagellins of several pathogenic bacteria, but not in Helicobacter pylori. Highly virulent H. pylori strains possess a type IV secretion system (T4SS) for delivery of virulence factors into gastric epithelial cells.
Microbiologists at the Friedrich Alexander University Erlangen-Nuremberg (Erlangen, Germany) and their colleagues investigated how the H. pylori manipulate the host's immune system in order to ensure their long-term survival in the stomach. A chronic inflammation is the most common cause for stomach illnesses. The team has identified a 'molecular switch' which uses a previously unknown mechanism to regulate the inflammation reaction in the stomach.
The interaction between H. pylori and stomach cells activates a syringe-like pilus structure referred to as a type IV secretion system. A protein, CagL, is presented at the surface of this structure which allows the bacterial toxin known as CagA protein to be delivered into the stomach cells. The injected CagA then re-programmes the host cell so that stomach cancer can develop. However, it now appears that CagL also has another important function. The protein is recognized by the immune system via the receptor TLR5. CagL imitates a TLR5 recognition motif in the flagellin protein of other pathogens, thereby controlling the human immune response.
Interestingly, this signaling pathway can be both switched on and switched off by the type IV secretion system, which is not thought to be the case with other bacteria. Presumably, H. pylori has exploited this signalling pathway over thousands of years of evolution to eliminate 'bothersome' bacterial competitors in the stomach. At the same time, CagL influences the congenital and adaptive immune system as well as the inflammation reaction in such a way that H. pylori itself is not recognized and therefore cannot be eliminated, a mechanism which is crucial for long-term infections with H. pylori in the stomach and triggering stomach disease.
The team also observed that TLR5 is no longer produced in healthy stomach cells and once an infection has been resolved. This indicates that the expression of this protein is a new indicator for stomach disease in humans triggered by H. pylori. The study was published on December 16, 2019 in the journal Nature Communications.
Related Links:
Friedrich Alexander University Erlangen-Nuremberg
Toll-like receptor TLR5 recognizes a conserved domain, termed D, that is present in flagellins of several pathogenic bacteria, but not in Helicobacter pylori. Highly virulent H. pylori strains possess a type IV secretion system (T4SS) for delivery of virulence factors into gastric epithelial cells.
Microbiologists at the Friedrich Alexander University Erlangen-Nuremberg (Erlangen, Germany) and their colleagues investigated how the H. pylori manipulate the host's immune system in order to ensure their long-term survival in the stomach. A chronic inflammation is the most common cause for stomach illnesses. The team has identified a 'molecular switch' which uses a previously unknown mechanism to regulate the inflammation reaction in the stomach.
The interaction between H. pylori and stomach cells activates a syringe-like pilus structure referred to as a type IV secretion system. A protein, CagL, is presented at the surface of this structure which allows the bacterial toxin known as CagA protein to be delivered into the stomach cells. The injected CagA then re-programmes the host cell so that stomach cancer can develop. However, it now appears that CagL also has another important function. The protein is recognized by the immune system via the receptor TLR5. CagL imitates a TLR5 recognition motif in the flagellin protein of other pathogens, thereby controlling the human immune response.
Interestingly, this signaling pathway can be both switched on and switched off by the type IV secretion system, which is not thought to be the case with other bacteria. Presumably, H. pylori has exploited this signalling pathway over thousands of years of evolution to eliminate 'bothersome' bacterial competitors in the stomach. At the same time, CagL influences the congenital and adaptive immune system as well as the inflammation reaction in such a way that H. pylori itself is not recognized and therefore cannot be eliminated, a mechanism which is crucial for long-term infections with H. pylori in the stomach and triggering stomach disease.
The team also observed that TLR5 is no longer produced in healthy stomach cells and once an infection has been resolved. This indicates that the expression of this protein is a new indicator for stomach disease in humans triggered by H. pylori. The study was published on December 16, 2019 in the journal Nature Communications.
Related Links:
Friedrich Alexander University Erlangen-Nuremberg
Latest Microbiology News
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more




.jpg)



